Literature DB >> 21955615

Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis.

Vasileios Kouranos1, George Dimopoulos, Antonios Vassias, Kostas N Syrigos.   

Abstract

Chemotherapy-induced neutropenia can cause fatal bacterial infections. Colony-stimulating factors (CSFs) are usually recommended as prophylaxis, while routine use of prophylactic antibiotics remains controversial. Based on our literature search in PubMed, quinolones and trimethoprim/sulfamethoxazole were the most frequently used prophylaxis, while CSFs were administered in 22.1% of patients. Lung cancer patients who received prophylactic antibiotics exhibited significantly fewer episodes of febrile neutropenia, fewer documented infections as well as shorter duration of related hospitalisations. Prophylactic use of wide spectrum antibiotics seems effective and should be considered as an alternative strategy in the prevention of chemotherapy-induced neutropenia in lung cancer patients.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21955615     DOI: 10.1016/j.canlet.2011.08.024

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992-2009.

Authors:  Yefei Zhang; Shuang-Shuang Fu; Xianglin L Du
Journal:  Med Oncol       Date:  2014-09-18       Impact factor: 3.064

Review 2.  Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients.

Authors:  Pashtoon Murtaza Kasi; Axel Grothey
Journal:  Drugs       Date:  2018-05       Impact factor: 9.546

3.  Using antimicrobial adjuvant therapy in cancer treatment: a review.

Authors:  Kenneth Alibek; Aliya Bekmurzayeva; Assel Mussabekova; Bolat Sultankulov
Journal:  Infect Agent Cancer       Date:  2012-11-20       Impact factor: 2.965

Review 4.  Toxicology of chemically modified graphene-based materials for medical application.

Authors:  Toktam Nezakati; Brian G Cousins; Alexander M Seifalian
Journal:  Arch Toxicol       Date:  2014-09-19       Impact factor: 5.153

5.  Graphene oxide loaded with tumor-targeted peptide and anti-cancer drugs for cancer target therapy.

Authors:  Ran Li; Yimei Wang; Jie Du; Xiangyu Wang; Ailin Duan; Ruifang Gao; Junyu Liu; Bing Li
Journal:  Sci Rep       Date:  2021-01-18       Impact factor: 4.379

6.  Development and Internal Validation of a Nomogram Used to Predict Chemotherapy-Induced Neutropenia in Non-Small Cell Lung Cancer Patients: A Retrospective Cohort Study.

Authors:  Wei Zou; Neng-Luan Xu
Journal:  Cancer Manag Res       Date:  2021-03-26       Impact factor: 3.989

7.  Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.

Authors:  Xiang Ji; Lisheng Xu; Pengfei Pan; Zhiyun Xu; Aihua Wang; Yu Li
Journal:  Thorac Cancer       Date:  2021-11-17       Impact factor: 3.500

8.  Water extract of deer bones activates macrophages and alleviates neutropenia.

Authors:  Han-Seok Choi; Soon Re Kim; Se Hyang Hong; Jin Mo Ku; Min Kyoung Kim; Hye Sook Seo; Sung-Gook Cho; Sangtae Shin; Yong Cheol Shin; Seong-Gyu Ko
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-09       Impact factor: 2.629

9.  Characterising the impact of pneumonia on outcome in non-small cell lung cancer: identifying preventative strategies.

Authors:  Akshay J Patel; Peter Nightingale; Babu Naidu; Mark T Drayson; Gary W Middleton; Alex Richter
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

Review 10.  Immunomodulatory effects of intestinal lung axis microecology and other factors on the prognosis of advanced non-small cell lung cancer.

Authors:  Changxing Shen; Yanbei Ren; Xu Zhang; Qing Xia; Ming Li; Changhui Wang; Lihong Fan
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.